Shots:
- The US FDA has received 510(k) application for MosaiQ AiPlex CTDplus multiplex microarray to improve & accelerate diagnosis of connective tissue diseases (CTDs)
- CTDplus diagnose CTDs using just 10μL of sample in one step, with its CTD microarray having 15 markers in each panel per pts—DFS70/LEDGF, CCP, dsDNA, Sm, Sm/RNP, U1RNP, Chromatin, Ribosomal P, SS-A 60, SS-B, TRIM21, Jo-1, CENP-B, Scl-70, & RNA Polymerase III
- CTDplus allows accurate serological evaluation with rapid results, detecting ~1275 CTD markers/hr. with RFID-tagged reagents & magazines, accelerating the process to reduce time, consumables, & errors while improving calibration, quality control, & lab efficiency
Ref: AliveDx | Image: AliveDx
Related News:- AliveDx Seeks US FDA’s 510(k) Clearance for MosaiQ AiPlex Multiplex Microarray
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
